WHO Recommends Lifestyle Changes Over GLP-1 Drugs for Child Obesity
The World Health Organization (WHO) has issued its first-ever guidelines on child and adolescent obesity, prioritizing lifestyle interventions such as dietary control, increased physical activity, and behavioral changes over the use of weight-loss drugs like GLP-1 agonists. The WHO cited a lack of sufficient evidence supporting the safety and efficacy of these medications in children when compared to non-pharmacological approaches. The guidelines emphasize prevention through public health strategies rather than pharmaceutical solutions for young patients. This stance reflects broader concerns about long-term drug use in pediatric populations, despite growing popularity among adults using GLP-1 drugs like semaglutide (Ozempic) and liraglutide (Saxenda). The decision may influence healthcare policies globally regarding the treatment of childhood obesity. Market observers are watching for potential implications on pharmaceutical companies developing or marketing these medications, particularly in pediatric applications.
Topics: obesity weight-loss drugs WHO guidelines